# NIH TCF Dev and Prod of SARS-CoV-2 Spike tetramers for B Cell Detection

> **NIH NIH N01** · EMORY UNIVERSITY · 2020 · $599,404

## Abstract

The NIH Tetramer Core Facility (TCF) distributes high quality reagents for detection of innate T cell and classical CD4 and CD8 T cell populations.  This Facility also conducts R&D to produce new reagents and improve existing tetramer technologies.  The  TCF is producing MHC class I and class II tetramers for isolation and characterization of SARS-CoV2-specific CD4 and CD8 T cells, and is also developing SARS-CoV-2 Spike protein tetramers for detection and characterization of SARS-CoV2 specific B cells. Thus far, 56  MHC tetramers have been distributed to the community, an additional 35 are in-process. Orders are expected to increase as COVID-related research increases. Additional reagents will be produced and distributed as new T cell epitopes and B cell antigen targets are identified.  These tetramer reagents will be invaluable tools for evaluation of adaptive immune responses in COVID patients or in response to candidate vaccines.

## Key facts

- **NIH application ID:** 10282181
- **Project number:** 75N93020D00005-0-759302000003-1
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** JOHN ALTMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $599,404
- **Award type:** —
- **Project period:** 2020-03-21 → 2027-03-20

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10282181

## Citation

> US National Institutes of Health, RePORTER application 10282181, NIH TCF Dev and Prod of SARS-CoV-2 Spike tetramers for B Cell Detection (75N93020D00005-0-759302000003-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10282181. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*